Top-News

Quest PharmaTech News

Geld Brief Änderung Brief
Keine aktuellen Kursdaten verfügbar
WKN: A0HGAA
ISIN: CA74836M1068
US-Symbol: QPTFF
Typ: Aktie

Quest PharmaTech News

01.06.21 - PR Newswire
Quest PharmaTech announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical Oncologists
Quest PharmaTech announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical Oncologists PR Newswire
09.11.20 - PR Newswire
Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company's Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and appoints Dr. Sunil Gupta as Chief Medical Officer
Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company's Lead Investigational Drug, Oregovomab, in Frontline ...
02.06.20 - PR Newswire
IIROC Trading Resumption - QPT
IIROC Trading Resumption - QPT Canada NewsWire
04.05.20 - PR Newswire
UPDATE - IIROC Trading Halt - QPT
UPDATE - IIROC Trading Halt - QPT Canada NewsWire
22.04.20 - PR Newswire
IIROC Trading Halt - QPT
IIROC Trading Halt - QPT Canada NewsWire
24.03.20 - PR Newswire
OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company's Lead Investigational Drug in Frontline Ovarian Cancer
OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company's Lead Investigational Drug in Frontline Ovarian Cancer PR Newswire
13.03.20 - PR Newswire
OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd.
OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd. PR Newswire
25.09.19 - PR Newswire
OncoQuest Receives "Notice of Allowance" for Patent Protection of the Administration Schedule of Oregovomab and Chemotherapy for Stage III-IV Ovarian Cancer Patients
OncoQuest Receives "Notice of Allowance" for Patent Protection of the Administration Schedule of Oregovomab and Chemotherapy for Stage III-IV Ovarian Cancer Patients PR ...
25.01.19 - PR Newswire
OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer
OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer PR Newswire
28.11.18 - PR Newswire
Quest PharmaTech Signs License Agreement with OncoCare Therapeutics to Develop and Commercialize Targeted Cancer Therapy Technology in the U.S.
Quest PharmaTech Signs License Agreement with OncoCare Therapeutics to Develop and Commercialize Targeted Cancer Therapy Technology in the U.S. PR Newswire
01.06.18 - PR Newswire
Abstract Describing Use of Oregovomab in Pancreatic Cancer to be Published in JCO as Part of ASCO 2018 Meeting
Abstract Describing Use of Oregovomab in Pancreatic Cancer to be Published in JCO as Part of ASCO 2018 Meeting PR Newswire
14.05.18 - PR Newswire
Dr. Eliel Bayever Joins OncoQuest as Chief Medical Officer
Dr. Eliel Bayever Joins OncoQuest as Chief Medical Officer PR Newswire
12.02.18 - PR Newswire
OncoQuest to Present at BIO CEO & Investor Conference
OncoQuest to Present at BIO CEO & Investor Conference PR Newswire
06.02.18 - PR Newswire
OncoQuest Completes US$6 Million Private Placement
OncoQuest Completes US$6 Million Private Placement PR Newswire
14.11.17 - PR Newswire
OncoQuest Announces Presentation of Pre-Clinical Data from its IgE Based Immunotherapy Platform Technology at the 32nd Annual Society for Immunotherapy of Cancer (SITC)
OncoQuest Announces Presentation of Pre-​Clinical Data from its IgE Based Immunotherapy Platform Technology at the 32nd Annual Society for Immunotherapy of Cancer (SITC) ...
07.11.17 - PR Newswire
OncoQuest Announces Presentation of Translational Immunology Data from Phase 2 Clinical Study Examining Oregovomab in Combination with Chemotherapy in Front Line Ovarian Cancer at the International Me
OncoQuest Announces Presentation of Translational Immunology Data from Phase 2 Clinical Study Examining Oregovomab in Combination with Chemotherapy in Front Line ...
02.11.17 - PR Newswire
OncoQuest Announces Collaboration with TESARO in Recurrent Ovarian Cancer Setting
OncoQuest Announces Collaboration with TESARO in Recurrent Ovarian Cancer Setting PR Newswire
26.07.17 - PR Newswire
First Patient Enrolled in OncoQuest's Phase 1/2 Study Combining Oregovomab with Hiltonol® in Recurrent Ovarian Cancer
First Patient Enrolled in OncoQuest's Phase 1/2 Study Combining Oregovomab with Hiltonol® in Recurrent Ovarian Cancer PR Newswire
27.06.17 - PR Newswire
OncoQuest Appoints Senior Biotech Investment Banker Hany Awadalla as Senior Vice President and Chief Financial Officer
OncoQuest Appoints Senior Biotech Investment Banker Hany Awadalla as Senior Vice President and Chief Financial Officer PR Newswire
27.06.17 - PR Newswire
OncoQuest Appoints Senior Biotech Investment Banker Hany Awadalla as Senior Vice President and Chief Financial Officer
OncoQuest Appoints Senior Biotech Investment Banker Hany Awadalla as Senior Vice President and Chief Financial Officer PR Newswire

Newssuche

Videos

newspaper
09:30 Uhr +21,95%
Technical Trading: S&P 500 Short Chance
S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »